AIDA: AI 评分 41/100 — AI 分析 (4月 2026)

Aida Pharmaceuticals, Inc. is a Chinese pharmaceutical company focused on developing, manufacturing, and marketing pharmaceutical and genetic products. The company's portfolio includes antibiotics, cardiovascular drugs, and anti-cancer therapies, primarily serving the mainland China market.

Key Facts: AI Score: 41/100 Sector: Healthcare

公司概况

概要：

Aida Pharmaceuticals, Inc., based in China, formulates, tests, manufactures, and markets pharmaceutical and genetic products, including antibiotics, cardiovascular, and anti-cancer drugs. With a 9.4% profit margin and 50.3% gross margin, the company operates in the competitive Chinese pharmaceutical market, facing both growth opportunities and regulatory challenges.

AIDA是做什么的？

Founded in 1999 and headquartered in Hangzhou, China, Aida Pharmaceuticals, Inc. is a pharmaceutical company engaged in the formulation, clinical testing, registration, manufacture, sales, and marketing of pharmaceutical and genetic products in mainland China. The company's product portfolio encompasses a range of therapeutic areas, including antibiotics, cardiovascular drugs, and anti-cancer therapies. Aida Pharmaceuticals provides its products in various forms, including powder for injection, liquid for intravenous injection, capsules, tablets, and ointments. Key products include Etimicin Sulfate, an injectable antibiotic, and rh-Apo2l, a biopharmaceutical therapy targeting cancers. Aida Pharmaceuticals operates within the Chinese pharmaceutical market, navigating a complex regulatory landscape and competitive environment. The company focuses on both generic and specialty drugs, aiming to address prevalent health needs in China. With 450 employees, Aida Pharmaceuticals strives to maintain a balance between innovation and affordability in its product offerings. The company's strategic focus remains on expanding its market presence within China while adhering to stringent quality control and regulatory standards.

AIDA的投资论点是什么？

Aida Pharmaceuticals, Inc. presents a mixed investment profile. The company's focus on the Chinese pharmaceutical market, with its aging population and increasing healthcare expenditure, offers growth potential. Aida's 9.4% profit margin and 50.3% gross margin indicate operational efficiency. Key growth catalysts include successful clinical trials and regulatory approvals for new drugs, particularly rh-Apo2l. However, the company faces risks associated with OTC market trading, intense competition from both domestic and international pharmaceutical companies, and potential regulatory changes in China. The company's high beta of 17.62 suggests significant volatility. Investors should carefully weigh these factors, considering the company's financial performance, market position, and the inherent risks of the pharmaceutical industry in China.

AIDA在哪个行业运营？

Aida Pharmaceuticals operates within the Chinese pharmaceutical market, a rapidly growing sector driven by an aging population, increasing healthcare expenditure, and government initiatives to improve healthcare access. The market is characterized by intense competition from both domestic and international players, including generic drug manufacturers and innovative biopharmaceutical companies. Regulatory changes and pricing pressures are significant factors shaping the industry landscape. Aida Pharmaceuticals competes with companies like BLMS, BTTX, CANQF, CENBF, and MJNE, navigating a complex environment to maintain market share and profitability. The company's focus on both generic and specialty drugs positions it to address a broad range of healthcare needs in China.

Drug Manufacturers - Specialty & Generic

Healthcare

AIDA有哪些增长机遇？

Expanding rh-Apo2l Market Penetration: Aida Pharmaceuticals has the opportunity to increase the market penetration of its rh-Apo2l biopharmaceutical therapy for cancers within China. The Chinese cancer therapeutics market is projected to reach $45 billion by 2028, driven by rising cancer incidence and improved diagnostic capabilities. Successful clinical trials and regulatory approvals for additional cancer indications could significantly boost rh-Apo2l sales. The company's competitive advantage lies in its local manufacturing and distribution network, allowing it to offer rh-Apo2l at a competitive price point compared to imported therapies. Timeline: Ongoing, with potential for significant revenue growth within the next 3-5 years.
Developing New Antibiotic Formulations: Aida Pharmaceuticals can leverage its expertise in antibiotic formulation to develop new and improved versions of existing antibiotics, addressing the growing problem of antibiotic resistance. The global market for antibiotics is expected to reach $44.6 billion by 2027. By focusing on developing formulations with improved efficacy and reduced side effects, Aida Pharmaceuticals can capture a significant share of the Chinese antibiotic market. The company's existing manufacturing infrastructure and regulatory expertise provide a competitive advantage. Timeline: 2-3 years for research and development, followed by clinical trials and regulatory approval.
Strategic Partnerships and Acquisitions: Aida Pharmaceuticals can pursue strategic partnerships and acquisitions to expand its product portfolio and market reach. Collaborating with other pharmaceutical companies or acquiring smaller firms with complementary products can accelerate growth and diversify revenue streams. The Chinese pharmaceutical market is consolidating, creating opportunities for strategic acquisitions. Aida Pharmaceuticals' financial stability and operational expertise make it an attractive partner for other companies. Timeline: Ongoing, with potential for significant impact within the next 1-2 years.
Expanding into Rural Markets: Aida Pharmaceuticals can expand its distribution network to reach underserved rural markets in China. These markets represent a significant growth opportunity, as access to healthcare is often limited. By establishing partnerships with local distributors and healthcare providers, Aida Pharmaceuticals can increase its market share and improve healthcare access for rural populations. Government initiatives to improve rural healthcare infrastructure will further support this expansion. Timeline: 3-5 years, requiring investment in distribution infrastructure and local partnerships.
Investing in Research and Development: Aida Pharmaceuticals can invest more heavily in research and development to discover and develop novel pharmaceutical products. This will allow the company to differentiate itself from competitors and capture a larger share of the market. Focusing on innovative therapies for prevalent diseases in China, such as cardiovascular disease and diabetes, can yield significant returns. Government support for pharmaceutical innovation provides additional incentives. Timeline: Long-term, requiring sustained investment and a focus on strategic research areas.

Aida Pharmaceuticals operates with a profit margin of 9.4%, reflecting its ability to generate earnings from its sales.
The company maintains a gross margin of 50.3%, indicating efficient cost management in its manufacturing and sales processes.
Aida Pharmaceuticals focuses on the Chinese pharmaceutical market, which is experiencing growth due to an aging population and increasing healthcare expenditure.
Key products include Etimicin Sulfate (antibiotic) and rh-Apo2l (anti-cancer therapy), targeting significant health needs in China.
The company's beta of 17.62 indicates high volatility compared to the overall market.

AIDA提供哪些产品和服务？

Formulates pharmaceutical products, including antibiotics, cardiovascular drugs, and anti-cancer therapies.
Conducts clinical testing to ensure the safety and efficacy of its products.
Registers its pharmaceutical products with regulatory authorities in China.
Manufactures pharmaceutical products in various forms, including injections, capsules, tablets, and ointments.
Sells and markets its products to healthcare providers and patients in mainland China.
Develops and commercializes genetic products, including biopharmaceutical therapies for cancers.

AIDA如何赚钱？

Develops and manufactures generic and specialty pharmaceutical products.
Markets and sells these products directly to hospitals, clinics, and pharmacies in mainland China.
Generates revenue through the sale of its pharmaceutical products.
Reinvests a portion of its revenue into research and development to create new products.

Hospitals and clinics throughout mainland China.
Pharmacies and drug stores.
Patients who purchase prescription medications.

Established presence and distribution network in mainland China.
Expertise in formulating and manufacturing pharmaceutical products.
Portfolio of both generic and specialty drugs.
Relationships with key healthcare providers and regulatory authorities in China.

什么因素可能推动AIDA股价上涨？

Upcoming: Clinical trial results for rh-Apo2l expected in Q4 2026 could drive positive market sentiment.
Ongoing: Expansion of distribution network into rural areas of China is expected to increase sales volume.
Ongoing: Government initiatives to improve healthcare access in China could benefit Aida Pharmaceuticals.

AIDA的主要风险是什么？

Potential: Regulatory changes in China could negatively impact the company's operations and profitability.
Potential: Patent expirations and biosimilar competition could erode market share.
Ongoing: Intense competition from both domestic and international pharmaceutical companies.
Ongoing: The company's reliance on the Chinese market exposes it to economic and political risks specific to that country.
Potential: The company's high beta of 17.62 indicates significant volatility.

AIDA的核心优势是什么？

Established presence in the Chinese pharmaceutical market.
Diverse product portfolio including antibiotics, cardiovascular drugs, and anti-cancer therapies.
Manufacturing capabilities for various drug formulations.
Existing relationships with healthcare providers and regulatory authorities.

AIDA的劣势是什么？

Reliance on the Chinese market, limiting geographic diversification.
Competition from both domestic and international pharmaceutical companies.
Potential vulnerability to regulatory changes and pricing pressures.
Limited brand recognition compared to larger multinational corporations.

AIDA有哪些机遇？

Expanding into underserved rural markets in China.
Developing new and improved drug formulations.
Acquiring smaller pharmaceutical companies with complementary products.
Partnering with international companies to access new markets and technologies.

AIDA面临哪些威胁？

Increasing competition from generic drug manufacturers.
Potential for patent expirations and biosimilar competition.
Changes in government regulations and healthcare policies.
Fluctuations in currency exchange rates.

AIDA的竞争对手是谁？

Bellicum Pharmaceuticals, Inc. — Focuses on cellular immunotherapies. — (BLMS)
Better Therapeutics, Inc. — Develops prescription digital therapeutics. — (BTTX)
বেঙ্গল গ্লাসওয়্যার লিমিটেড — Unknown differentiation. — (CANQF)
Cen Biotech, Inc. — Focuses on medical cannabis. — (CENBF)
Mine One Blockchain Inc. — Focuses on blockchain and cryptocurrency solutions. — (MJNE)

Key Metrics

MoonshotScore: 41/100

Company Profile

CEO: Biao Jin
Headquarters: Hangzhou, CN
Employees: 450
Founded: 2005

AI Insight

AI analysis pending for AIDA

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Aida Pharmaceuticals, Inc. do?

Aida Pharmaceuticals, Inc. is a Chinese pharmaceutical company that formulates, tests, manufactures, and markets a range of pharmaceutical and genetic products. Its portfolio includes antibiotics like Etimicin Sulfate, cardiovascular drugs, and anti-cancer therapies such as rh-Apo2l. The company primarily serves the mainland China market, providing these products in various forms like injections, capsules, and tablets. Aida focuses on both generic and specialty drugs, aiming to address prevalent health needs in China through its established distribution network.

What do analysts say about AIDA stock?

As of March 17, 2026, formal analyst coverage of AIDA is limited due to its OTC listing. Key valuation metrics like P/E ratio are currently at 0.00. The company's growth considerations revolve around successful clinical trials for drugs like rh-Apo2l and expansion into rural markets. Investors should focus on the company's financial disclosures, regulatory approvals, and competitive positioning within the Chinese pharmaceutical market. The company's high beta suggests significant volatility.

What are the main risks for AIDA?

Aida Pharmaceuticals faces several risks, including intense competition from both domestic and international pharmaceutical companies in China. Regulatory changes and pricing pressures within the Chinese healthcare system pose ongoing challenges. The company's reliance on a single geographic market (China) exposes it to economic and political risks specific to that region. Additionally, potential patent expirations and the emergence of biosimilar competition could erode market share and profitability. Investing in an OTC-listed company also carries inherent risks related to liquidity and disclosure.